MG
RLMD icon

Michael Gelband’s Relmada Therapeutics RLMD Stock Holding History

Michael Gelband’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,883
Closed -$333K – 2017
2025
Q4 		$333K Buy
+68,883
New +$231K ﹤0.01% 1281
2024
Q4 		– Sell
-68,000
Closed -$220K – 1963
2024
Q3 		$220K Buy
+68,000
New +$220K ﹤0.01% 1433
2022
Q4 		– Sell
-29,786
Closed -$1.1M – 2052
2022
Q3 		$1.1M Buy
29,786
+11,531
+63% +$319K 0.01% 1070
2022
Q2 		$347K Buy
+18,255
New +$398K ﹤0.01% 1484
2020
Q2 		– Sell
-28,252
Closed -$964K – 1988
2020
Q1 		$964K Buy
28,252
+16,497
+140% +$665K 0.05% 317
2019
Q4 		$458K Buy
+11,755
New +$357K 0.01% 905

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SSC
Spruce Street Capital New York $510M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Michael Gelband's RLMD Position: Q1 2026 in Review

Michael Gelband sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 68,883 shares — an estimated $333K sold.

Michael Gelband first reported a position in RLMD in Q4 2019 and held it in 6 quarters. The position peaked at $1.1M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Michael Gelband reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 68,883 Relmada Therapeutics shares in Q1 2026, an estimated $333K.
  • Michael Gelband first reported a position in Relmada Therapeutics in Q4 2019 and held it in 6 quarters.
  • Michael Gelband's Relmada Therapeutics position peaked at $1.1M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.